Pfizer Inc. $PFE Shares Sold by High Note Wealth LLC

High Note Wealth LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 13.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,481 shares of the biopharmaceutical company’s stock after selling 1,165 shares during the quarter. High Note Wealth LLC’s holdings in Pfizer were worth $181,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC raised its holdings in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC increased its stake in Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after purchasing an additional 2,087 shares during the last quarter. Miracle Mile Advisors LLC raised its stake in Pfizer by 6.2% during the 1st quarter. Miracle Mile Advisors LLC now owns 233,234 shares of the biopharmaceutical company’s stock valued at $5,910,000 after acquiring an additional 13,534 shares in the last quarter. Central Bank & Trust Co. boosted its position in shares of Pfizer by 18.8% during the 1st quarter. Central Bank & Trust Co. now owns 19,869 shares of the biopharmaceutical company’s stock valued at $503,000 after purchasing an additional 3,140 shares in the last quarter. Finally, AHL Investment Management Inc. raised its holdings in shares of Pfizer by 7.4% during the first quarter. AHL Investment Management Inc. now owns 91,782 shares of the biopharmaceutical company’s stock valued at $2,326,000 after acquiring an additional 6,345 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Down 3.4%

PFE stock opened at $26.45 on Tuesday. The firm has a market capitalization of $150.38 billion, a price-to-earnings ratio of 14.07, a PEG ratio of 0.88 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The company’s 50 day moving average price is $24.72 and its 200 day moving average price is $24.12. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter last year, the firm earned $0.60 earnings per share. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Bank of America raised their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday. UBS Group reiterated a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a research report on Wednesday, October 1st. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Morgan Stanley raised their target price on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research note on Saturday, September 27th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $28.41.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.